{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:13:57Z","timestamp":1747178037267,"version":"3.40.5"},"reference-count":15,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2023,9,19]]},"DOI":"10.1080\/10428194.2023.2235042","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T12:08:36Z","timestamp":1690459716000},"page":"1864-1869","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed\/refractory patients with multiple myeloma"],"prefix":"10.1080","volume":"64","author":[{"given":"Paula","family":"Rodr\u00edguez Otero","sequence":"first","affiliation":[{"name":"Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Towle","sequence":"additional","affiliation":[{"name":"Evidence Synthesis &amp; Decision Modeling, PRECISIONheor, Vancouver, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Cope","sequence":"additional","affiliation":[{"name":"Evidence Synthesis &amp; Decision Modeling, PRECISIONheor, Vancouver, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clyde","family":"Caisip","sequence":"additional","affiliation":[{"name":"Evidence Synthesis &amp; Decision Modeling, PRECISIONheor, Vancouver, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faith E.","family":"Davies","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[{"name":"Department of Haematology, University Hospital Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas S.","family":"Marshall","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Korinna","family":"Karampampa","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Uxbridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Ayers","sequence":"additional","affiliation":[{"name":"Evidence Synthesis &amp; Decision Modeling, PRECISIONheor, Vancouver, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2318-8627","authenticated-orcid":false,"given":"Ali","family":"Mojebi","sequence":"additional","affiliation":[{"name":"Evidence Synthesis &amp; Decision Modeling, PRECISIONheor, Vancouver, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Braverman","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Farrell","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devender","family":"Dhanda","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.01.011"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00695-5"},{"key":"e_1_3_5_4_1","unstructured":"European Medicines Agency (EMA). ABECMA (idecabtagene vicleucel); 2021 [updated 2022 Dec 21]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/abecma-epar-product-information_en.pdf"},{"key":"e_1_3_5_5_1","unstructured":"Food and Drug Administration. ABECMA (idecabtagene vicleucel); 2021 [updated 2021 Apr 21]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/abecma-idecabtagene-vicleucel"},{"key":"e_1_3_5_6_1","unstructured":"European Medicines Agency (EMA). BLENREP (belantamab mafodotin): EU summary of product characteristics; 2020. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2020\/20200825148987\/anx_148987_en.pdf"},{"key":"e_1_3_5_7_1","unstructured":"GlaxoSmithKline. GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorization [press release]; 2023 [cited 2023 Jun 19]. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-provides-update-on-blenrep-us-marketing-authorisation\/"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1913143"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000849816.07364.24"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)02101-7"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33809"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005913"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3391"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2023.2235042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T06:33:24Z","timestamp":1708756404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2023.2235042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,9,19]]}},"alternative-id":["10.1080\/10428194.2023.2235042"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2023.2235042","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"type":"print","value":"1042-8194"},{"type":"electronic","value":"1029-2403"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}